D-Day for Obamacare: Trading the Outcomes – CNBC

June 27, 2012 Posted By: Leave a comment
However, if the rest of the law stands, Mark Schoenebaum of ISI Group says a hidden impact could be a drag on earnings across biotech and pharma broadly, because the fees and dings in the legislation would remain in tact. For example, the legislation ...
Subscribe to LegalLaw247.Com Newsletter

Leave a Reply

Your email address will not be published. Required fields are marked *

*

CAPTCHA Image

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>